Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Dexamethasone or Adrenaline in Inferior Alveolar Nerve Block

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04850885
Recruitment Status : Completed
First Posted : April 20, 2021
Last Update Posted : April 22, 2021
Sponsor:
Collaborator:
National Medical College, Birgunj, Nepal
Information provided by (Responsible Party):
Dr Saroj Prasad Deo, Tribhuvan University, Nepal

Brief Summary:

Oral and dental professionals were responsible for the discovery of anaesthesia, given their close day-to-day contact with pain and, hence, their motivation to seek the means to alleviate it. Currently, third molar surgery (TMS) has become the model most frequently used in acute pain trials because third molar surgery (TMS) is simple and frequently used procedure with pain moderate or severe in intensity, as well as sufficient numbers of patients, are available for the required sample size for the studies.

Effective local anaesthesia is arguably the single most important pillar upon which modern dentistry stands. Many agents are not available in the markets of Nepal that provide a rapid onset of surgical anaesthesia with adequate duration. The current study is designed to search for a better quality of perioperative analgesics with a single injection of dexamethasone and lignocaine in IANB preoperatively during TMS. The purpose of the current study is to evaluate the effectiveness and safety profiles of coadministration of dexamethasone (4mg/ml) or adrenaline ( 0.01mg/ml) with lignocaine 2% in IANB during TMS. Best of my knowledge this is a unique and novel clinical trial, probably the first trial which aim to overcome three principal challenges of local anaesthesia with a single injection during TMS.


Condition or disease Intervention/treatment Phase
Oral Surgical Procedure Drug: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The non-probability convenience sampling method was used to select the subjects for this study based on availability and willingness to take part. Total 406 patients presented in department oral and maxillofacial surgery were examined and screened for the study. Detailed history, examination and radiograph ( orthopantomogram) were taken to evaluate disease and mandibular foramina. The sixty subjects were assigned randomly into two groups; DXN or ADN. Subjects were received either Mixture A and Mixture B for IANB on side of surgery. Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline) whereas Group DXN was received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml).
Masking: Double (Participant, Investigator)
Masking Description: The blinding of this clinical study was done by confidential supporting staff. The supporting staff was hired for documentation and blinding. Details of role and responsibilities were described to him/her. The study materials ie 30 ml vial of lignocaine 2% (20 mg/ml Xylocaine, AstraZeneca, India); 2 ml in dexamethasone ( 4mg/ml Inj Dexona, Zydus Aliadac, India), in adrenaline 1mg/ml (Actiza, India), normal saline (NS) and identical 5ml syringe and file were given to supporting staff. On the day of surgery, he/she prepared drugs for IANB either the 4 ml Mixture B ( 2ml dexamethasone 4mg/ml + 2ml lignocaine 20mg/ml ) or 4ml Mixture A ( 2ml lignocaine 20mg/ml + 2ml adrenaline 0.01mg/ml, freshly prepared ) in 5 ml identical syringes as mentioned in block randomization chart. The patient name and age were documented the same in a file and a special code was generated and labelled on syringes.
Primary Purpose: Supportive Care
Official Title: The Co-administration of Dexamethasone or Adrenaline With Lignocaine 2% Prologues Duration in Inferior Alveolar Nerve Block- :A Comparative Study
Actual Study Start Date : August 1, 2020
Actual Primary Completion Date : February 2, 2021
Actual Study Completion Date : February 28, 2021


Arm Intervention/treatment
Experimental: Dexamethasone Group ( Group DXN)
Group DXN has received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml)
Drug: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml
The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
Other Name: inj adreanaline 0.01mg/ml and inj lignocaine 20mg/ml

Active Comparator: Adreanaline Group ( Group ADN)
Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline)
Drug: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml
The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
Other Name: inj adreanaline 0.01mg/ml and inj lignocaine 20mg/ml




Primary Outcome Measures :
  1. onset time and duration of anaesthesia. [ Time Frame: one week post operative ]

    Postoperative pain is rated on a 10 cm visual analogue scale (VAS) anchored by the verbal description "no pain" (0) and "very severe pain (9)" at every half an hourly up to 24 hours. When the patients began to experience moderate pain (VAS 4-5); it was considered that the anaesthetic effect of the test drugs was terminated. Then patient instructed to take analgesic only prescribed in the researcher. They were asked to record the time every time up to 7 days postoperatively.

    The nerve block was assessed objectively every two minute time interval (2, 4, 6, 8, 10 and 15 minute) with the application of cold sprit swabs/ice pack in the lower lip and by the response to atraumatic prick with the blunt instrument in a buccal and lingual mucoperiosteum in relation to 1st molar and canine teeth. The time of complete nerve block was achieved before starting the surgical procedure. T



Secondary Outcome Measures :
  1. post operative facial edema [ Time Frame: one week post operative ]
    A surgical outcome facial swelling (edema) and trismus were determined by measuring change in facial contour and inability in mouth opening respectively. Clinical measurements of maximum interincisal distance and facial contours were measured at preoperative day (baseline) and postoperatively days (2nd and 7th day). The facial contour was measured by flexible tape from the tragus to pogonian (Figure ).

  2. trismus [ Time Frame: one week post operative ]
    Intercessor distance was measured between upper and lower central incisors after asking the patient to open the mouth fully with the help of a digital vernier calliper. The examiner was the same one who assessed them preoperatively. Facial oedema and trismus were recorded as the differences between postoperative and preoperative (baseline) values at these appointments.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • patients above age 18 who need oral surgery under local anaesthesia and could understand and willing to take part in the study were selected.
  • contraindications to Dexamethasone (i.e., peptic ulcer, renal insufficiency, pregnant women or lactating females ),
  • allergy to NSAIDs ie piroxicam
  • ASA physical status > III
  • any type of surgery other than a mention surgery performed under general anaesthesia

    --patients with any condition precluding the limitation of intra-operative trial drugs ( lignocaine, adrenaline) administration (i.e., significant coronary artery disease, congestive heart failure)

  • those receiving any premedications (including opioids, benzodiazepines, and clonidine )
  • antibiotics or anti-inflammatory drugs within two weeks of the study entry. Also, radiograph showing high and bifid mandibular foramen were non included.

Exclusion Criteria:

  • Subject who had to consume analgesic drugs other than the piroxicam 20 mg
  • The subjects who did not respond on the VAS scale for 24 hourly and did not come for follow-up for 2nd and 7th postoperatively.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04850885


Locations
Layout table for location information
Nepal
Saroj Prasad Deo
Birganj, Two, Nepal, 43000
Sponsors and Collaborators
Tribhuvan University, Nepal
National Medical College, Birgunj, Nepal
Investigators
Layout table for investigator information
Principal Investigator: Saroj P Deo, 10+2 Tribhuvan University, Nepal
Publications:
Layout table for additonal information
Responsible Party: Dr Saroj Prasad Deo, Associate professor, Tribhuvan University, Nepal
ClinicalTrials.gov Identifier: NCT04850885    
Other Study ID Numbers: F-NMC/422/075/076
First Posted: April 20, 2021    Key Record Dates
Last Update Posted: April 22, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Dr Saroj Prasad Deo, Tribhuvan University, Nepal:
Dexamethasone; Inferior alveolar nerve block
Additional relevant MeSH terms:
Layout table for MeSH terms
Dexamethasone
Lidocaine
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action